Featured Research

from universities, journals, and other organizations

New cancer treatment gives hope to lymphoma and leukemia patients

Date:
February 26, 2010
Source:
The Translational Genomics Research Institute
Summary:
Cancer researchers have high hopes for a new therapy for patients with certain types of lymphoma and leukemia.

Cancer researchers have high hopes for a new therapy for patients with certain types of lymphoma and leukemia.

PCI-32765 is a new drug being assessed in a Phase I clinical trial at the Virginia G. Piper Cancer Center in collaboration with the Clinical Division of the Translational Genomics Research Institute (TGen).

This is one of 35 such trials under way through a partnership between the Virginia G. Piper Cancer Center at Scottsdale Healthcare and TGen, which enables molecular and genomic discoveries to reach patients through Phase I trials as quickly as possible.

"Progress in developing new treatments for cancer has been painfully slow as only 2-4 percent of all cancer patients enroll in clinical trials. This is especially true for uncommon cancers such as leukemia's and lymphomas," said Dr. Raoul Tibes, Director of the Hematological Malignancies Program at the Virginia G. Piper Cancer Center and an Associate Investigator at TGen.

Clinical trials test the safety and effectiveness of new drugs prior to approval by the U.S. Food and Drug Administration. Participants are volunteers for whom other cancer treatments have failed. Arizona is one of many states in which clinical trials often are covered by health insurance.

"This study is going very well. It is a very promising agent,'' Dr. Tibes said of PCI-32765, which uniquely targets the molecular abnormalities of lymphoma cells. "This is a recently identified cancer mechanism that we are going after with this drug in lymphoma cells."

Bruton-tyrosine-kinase, or Btk, is an enzyme needed to maintain B-lymphocytes function. B- lymphocytes are the cells that make antibodies for the immune system.

Too little Btk causes a disease called Bruton's agammaglobulinemia, in which the B-lymphocytes fail to mature and produce antibodies, leading to infections.

Too much Btk is involved in constantly stimulating the proliferation and spread of lymphoma and leukemia cells.

PCI-32765, produced by Pharmacyclics of Sunnyvale, Calif., inhibits Btk. Preclinical studies showed PCI-32765 arrested cancer cell growth and caused cancer cell death.

"This is the Yin and Yang of two diseases," said Dr. Tibes. In one there is not enough Btk; in the other, too much. "We are exploiting a natural occurring phenomenon, an enzyme that is turned around in cancer, and now we have a drug against it."

Dr. Tibes, the principal investigator for the clinical trial, said PCI-32765 is at the frontier of research and offers a new therapy option for patients with advanced lymphomas and chronic lymphocytic leukemia.

Patients with a variety of lymphomas can participate in the clinical trial, including those with aggressive diffuse large B-Cell and mantle cell lymphoma, as well as patients with follicular lymphoma.

"Perhaps there is a genetic context under which certain patients may be more responsive. We want to find those patients and explore the possibilities for their benefit in this ongoing study,'' said Dr. Ramesh K. Ramanathan, research medical director.


Story Source:

The above story is based on materials provided by The Translational Genomics Research Institute. Note: Materials may be edited for content and length.


Cite This Page:

The Translational Genomics Research Institute. "New cancer treatment gives hope to lymphoma and leukemia patients." ScienceDaily. ScienceDaily, 26 February 2010. <www.sciencedaily.com/releases/2010/02/100226161434.htm>.
The Translational Genomics Research Institute. (2010, February 26). New cancer treatment gives hope to lymphoma and leukemia patients. ScienceDaily. Retrieved August 30, 2014 from www.sciencedaily.com/releases/2010/02/100226161434.htm
The Translational Genomics Research Institute. "New cancer treatment gives hope to lymphoma and leukemia patients." ScienceDaily. www.sciencedaily.com/releases/2010/02/100226161434.htm (accessed August 30, 2014).

Share This




More Health & Medicine News

Saturday, August 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
3 Things To Know About The Ebola Outbreak's Progression

3 Things To Know About The Ebola Outbreak's Progression

Newsy (Aug. 29, 2014) Here are three things you need to know about the deadly Ebola outbreak's progression this week. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins